American Century Companies Inc. Sells 2,124,050 Shares of Kenvue Inc. (NYSE:KVUE)

American Century Companies Inc. lessened its position in Kenvue Inc. (NYSE:KVUE) by 10.1% during the fourth quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 18,867,138 shares of the company’s stock after selling 2,124,050 shares during the quarter. American Century Companies Inc.’s holdings in Kenvue were worth $402,813,000 as of its most recent filing with the Securities & Exchange Commission.

A number of other institutional investors have also added to or reduced their stakes in the company. Alerus Financial NA increased its stake in Kenvue by 0.3% in the third quarter. Alerus Financial NA now owns 191,345 shares of the company’s stock valued at $4,426,000 after acquiring an additional 491 shares during the last quarter. Kiley Juergens Wealth Management LLC increased its stake in Kenvue by 1.9% in the fourth quarter. Kiley Juergens Wealth Management LLC now owns 27,110 shares of the company’s stock valued at $579,000 after acquiring an additional 500 shares during the last quarter. Principle Wealth Partners LLC increased its stake in Kenvue by 3.7% in the fourth quarter. Principle Wealth Partners LLC now owns 14,194 shares of the company’s stock valued at $303,000 after acquiring an additional 500 shares during the last quarter. White Pine Capital LLC increased its stake in Kenvue by 1.0% in the fourth quarter. White Pine Capital LLC now owns 54,572 shares of the company’s stock valued at $1,165,000 after acquiring an additional 542 shares during the last quarter. Finally, Deseret Mutual Benefit Administrators increased its stake in Kenvue by 29.0% in the fourth quarter. Deseret Mutual Benefit Administrators now owns 2,528 shares of the company’s stock valued at $54,000 after acquiring an additional 568 shares during the last quarter. Institutional investors own 97.64% of the company’s stock.

Kenvue Stock Performance

Kenvue stock opened at $23.34 on Friday. The company has a current ratio of 1.00, a quick ratio of 0.69 and a debt-to-equity ratio of 0.66. The firm has a 50-day moving average of $22.08 and a 200-day moving average of $22.43. The firm has a market cap of $44.61 billion, a P/E ratio of 44.04, a P/E/G ratio of 2.62 and a beta of 1.25. Kenvue Inc. has a 1-year low of $17.67 and a 1-year high of $24.46.

Kenvue (NYSE:KVUE) last posted its earnings results on Thursday, February 6th. The company reported $0.26 earnings per share for the quarter, hitting analysts’ consensus estimates of $0.26. Kenvue had a net margin of 6.66% and a return on equity of 20.97%. Sell-side analysts expect that Kenvue Inc. will post 1.14 EPS for the current year.

Kenvue Announces Dividend

The company also recently disclosed a quarterly dividend, which was paid on Wednesday, February 26th. Shareholders of record on Wednesday, February 12th were given a dividend of $0.205 per share. The ex-dividend date of this dividend was Wednesday, February 12th. This represents a $0.82 annualized dividend and a yield of 3.51%. Kenvue’s payout ratio is 154.72%.

Wall Street Analyst Weigh In

Several analysts have issued reports on the stock. Barclays cut their price target on shares of Kenvue from $23.00 to $21.00 and set an “equal weight” rating for the company in a research report on Friday, January 17th. Royal Bank of Canada restated a “sector perform” rating and set a $24.00 price target on shares of Kenvue in a research report on Monday, February 3rd. Piper Sandler upped their price target on shares of Kenvue from $24.00 to $27.00 and gave the company an “overweight” rating in a research report on Monday, February 24th. Canaccord Genuity Group upped their price target on shares of Kenvue from $24.00 to $29.00 and gave the company a “buy” rating in a research report on Wednesday, March 5th. Finally, Deutsche Bank Aktiengesellschaft lowered shares of Kenvue from a “buy” rating to a “hold” rating and cut their price target for the company from $25.00 to $24.00 in a research report on Thursday, December 12th. One equities research analyst has rated the stock with a sell rating, seven have given a hold rating and five have given a buy rating to the company’s stock. Based on data from MarketBeat.com, Kenvue has a consensus rating of “Hold” and an average target price of $23.75.

About Kenvue

Kenvue Inc operates as a consumer health company worldwide. The company operates through three segments: Self Care, Skin Health and Beauty, and Essential Health. The Self Care segment offers cough, cold and allergy, pain care, digestive health, smoking cessation, eye care, and other products under the Tylenol, Motrin, Benadryl, Nicorette, Zarbee's, ORSLTM, Rhinocort, Calpol, and Zyrtec brands.